We are live on !
Find out more
Boxer Capital Portfolio holdings
AUM
$2.04B
Turnover
20.83%
1-Year Est. Return
108.39%
This Fund
S&P 500
This Quarter Est. Return
+17.02%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.1%
10 Year Est. Return
–
AUM
$2.04B
AUM Growth
+$139M
(+7.3%)
Cap. Flow
+$41.9M
Cap. Flow % of AUM
Cap. Flow %
2.06%
Top 10 Holdings %
Top 10 Hldgs %
54.88%
Holding
72
New
11
Increased
1
Reduced
5
Closed
4
Avg Time Held
2.3
years
Top 10 Avg Time Held
2.7
years
Top 20 Avg Time Held
2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$19.9M |
| 2 |
uniQure
QURE
|
+$14.5M |
| 3 |
Nurix Therapeutics
NRIX
|
+$12.8M |
| 4 |
Apogee Therapeutics
APGE
|
+$8.58M |
| 5 |
Instil Bio
TIL
|
+$8.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fate Therapeutics
FATE
|
+$12.7M |
| 2 |
Allogene Therapeutics
ALLO
|
+$8.97M |
| 3 |
Nkarta
NKTX
|
+$8.97M |
| 4 |
Poseida Therapeutics, Inc. Common Stock
PSTX
|
+$7.66M |
| 5 |
Prelude Therapeutics
PRLD
|
+$3.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Miscellaneous | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Kymera Therapeutics
KYMR
$9.39B
| $21.3M | 1.05% |
+450,000
| New | +$19.9M |
2024 Q3
0 quarters
|
|
27
Spyre Therapeutics
SYRE
$8.69B
| $20.5M | 1.01% |
696,480
| – | – |
2023 Q4
3 quarters
|
|
28
Kura Oncology
KURA
$880M
| $19.5M | 0.96% |
1,000,000
| – | – |
2024 Q1
2 quarters
|
|
29
DELISTED
KalVista Pharmaceuticals
KALV
| $18.4M | 0.9% |
1,590,000
| – | – |
2023 Q1
6 quarters
|
|
|
30
Nkarta
NKTX
$126M
| $18.2M | 0.89% |
4,029,606
-1,577,744
| -28% | -$8.97M |
2023 Q4
3 quarters
|
|
31
Oric Pharmaceuticals
ORIC
$1.43B
| $17.8M | 0.87% |
1,732,571
| – | – |
2020 Q4
15 quarters
|
|
32
Structure Therapeutics
GPCR
$1.57B
| $17.6M | 0.86% |
400,000
| – | – |
2023 Q4
3 quarters
|
|
|
33
Fate Therapeutics
FATE
$247M
| $17.4M | 0.85% |
4,960,910
-3,255,000
| -40% | -$12.7M |
2021 Q4
11 quarters
|
|
34
Enliven Therapeutics
ELVN
$3.07B
| $17.1M | 0.84% |
671,358
| – | – |
2023 Q1
6 quarters
|
|
35
Replimune Group
REPL
$1.1B
| $16.8M | 0.83% |
1,536,341
| – | – |
2024 Q2
1 quarter
|
|
36
DELISTED
Day One Biopharmaceuticals
DAWN
| $16.6M | 0.81% |
1,189,943
| – | – |
2021 Q2
13 quarters
|
|
37
Cullinan Oncology
CGEM
$956M
| $15.2M | 0.75% |
907,895
+250,000
| +38% | +$4.43M |
2024 Q2
1 quarter
|
|
38
Arvinas
ARVN
$494M
| $15M | 0.74% |
608,614
| – | – |
2023 Q4
3 quarters
|
|
39
Climb Bio
CLYM
$623M
| $13.3M | 0.65% |
2,603,190
| – | – |
2024 Q2
1 quarter
|
|
40
Relay Therapeutics
RLAY
$4.04B
| $12.9M | 0.63% |
1,819,132
| – | – |
2020 Q3
16 quarters
|
|
|
41
Nurix Therapeutics
NRIX
$2.84B
| $12.7M | 0.62% |
+563,067
| New | +$12.8M |
2024 Q3
0 quarters
|
|
42
Prothena Corp
PRTA
$413M
| $11.5M | 0.57% |
690,000
| – | – |
2021 Q3
12 quarters
|
|
|
43
uniQure
QURE
$1.57B
| $11M | 0.54% |
+2,225,000
| New | +$14.5M |
2024 Q3
0 quarters
|
|
|
44
DELISTED
Apogee Therapeutics
APGE
| $10.5M | 0.52% |
+179,000
| New | +$8.58M |
2024 Q3
0 quarters
|
|
45
Olema Pharmaceuticals
OLMA
$615M
| $7.76M | 0.38% |
650,000
| – | – |
2024 Q2
1 quarter
|
|
46
Iovance Biotherapeutics
IOVA
$6.63B
| $7.04M | 0.35% |
750,000
| – | – |
2021 Q3
12 quarters
|
|
47
Century Therapeutics
IPSC
$295M
| $6.67M | 0.33% |
3,900,000
-1,001,603
| -20% | -$1.96M |
2024 Q1
2 quarters
|
|
48
Jasper Therapeutics
JSPR
$16.8M
| $6.58M | 0.32% |
350,000
| – | – |
2024 Q1
2 quarters
|
|
49
Sana Biotechnology
SANA
$703M
| $6.43M | 0.32% |
1,545,000
| – | – |
2024 Q1
2 quarters
|
|
50
DELISTED
Terns Pharmaceuticals
TERN
| $6.27M | 0.31% |
+752,000
| New | +$6.19M |
2024 Q3
0 quarters
|
|
Similar funds
Boxer Capital's Q3 2024 Portfolio in Review
As of Q3 2024, Boxer Capital held 72 positions worth $2.04B, up 7.3% from $1.9B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Boxer Capital's Q3 2024 filing shows 11 new, 1 increased, 5 reduced and 4 closed positions. Its largest new stake was Kymera Therapeutics: 450,000 shares worth $21.3M. The largest sale was Fate Therapeutics, an estimated $12.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Boxer Capital's largest Q3 2024 buy was Kymera Therapeutics: 450,000 shares worth $21.3M.
- Boxer Capital added most to Cullinan Oncology in Q3 2024, an estimated $4.43M increase.
- Boxer Capital's biggest Q3 2024 reduction was Fate Therapeutics, cutting an estimated $12.7M.
- Boxer Capital fully exited Allogene Therapeutics in Q3 2024, selling an estimated $8.97M.
- Boxer Capital's ten largest holdings make up 55% of its $2.04B portfolio in Q3 2024.
- Boxer Capital opened 11 new positions and closed 4 in Q3 2024.
- Boxer Capital's portfolio value rose 7.3% quarter-over-quarter to $2.04B.
Based on Boxer Capital's 13F filing for Q3 2024, filed 14 Nov 2024.